Literature DB >> 30099341

Leucodin attenuates inflammatory response in macrophages and lipid accumulation in steatotic hepatocytes via P2x7 receptor pathway: A potential role in alcoholic liver disease.

Yue Shang1, Xi-Feng Li2, Ming-Ji Jin1, Ying Li1, Yan-Ling Wu1, Quan Jin1, Yu Zhang1, Xia Li1, Min Jiang1, Ben-Wen Cui1, Li-Hua Lian3, Ji-Xing Nan4.   

Abstract

The current study was aimed to reveal that leucodin, a sesquiterpene lactone from Artemisia capillaris could inhibit the inflammatory response in macrophages and the lipid accumulation in hepatocytes via P2x7R-NLRP3 inflammasome activation. Several types of macrophages including mouse peritoneal macrophages, mouse bone marrow-derived macrophages and human macrophages THP-1 cells were pretreated with different concentrations of leucodin for 1 h and then stimulated with LPS and ATP. LPS plus ATP initiated IL-1β cleavage and release in mouse peritoneal macrophages and peaked at 4 h. Leucodin did not show significant toxicity within 200 μM and effectively inhibited pro-IL-1β cleavage and release of mature-IL-1β in macrophages. Also, P2x7R antagonist and caspase-1 inhibitor also decreased IL-1β release and cleavage. Additionally, leucodin suppressed P2x7R, TLR4 and NLRP3 expression in LPS/ATP-stimulated macrophages. HepG2 cells were pretreated with different concentrations of leucodin for 1 h and then exposed to ethanol for 24 h. Leucodin suppressed lipid accumulation and enhanced phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in HepG2 cells exposed to ethanol. In addition, leucodin inhibited the expression of sterol regulatory element binding protein-1 (SREBP1) and ACC in ethanol-treated HepG2 cells. Leucodin possessed the capacity for inhibiting inflammatory response in macrophages and suppressing lipid accumulation in hepatocytes, suggesting a promising therapeutic potential targeting inflammation and lipid metabolism in alcoholic liver disease.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alcoholic liver steatosis; Inflammation; Leucodin; NLRP3; P2x7R

Mesh:

Substances:

Year:  2018        PMID: 30099341     DOI: 10.1016/j.biopha.2018.08.009

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  P2X7 receptor-targeted regulation by tetrahydroxystilbene glucoside in alcoholic hepatosteatosis: A new strategy towards macrophage-hepatocyte crosstalk.

Authors:  Yu Zhang; Min Jiang; Ben-Wen Cui; Cheng Hua Jin; Yan-Ling Wu; Yue Shang; Hong-Xu Yang; Mei Wu; Jian Liu; Chun-Ying Qiao; Zi-Ying Zhan; Huan Ye; Guang-Hao Zheng; Quan Jin; Li-Hua Lian; Ji-Xing Nan
Journal:  Br J Pharmacol       Date:  2020-02-23       Impact factor: 8.739

Review 2.  Purinergic signaling in hepatic disease.

Authors:  E Velázquez-Miranda; M Díaz-Muñoz; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2019-10-01       Impact factor: 3.765

Review 3.  Inflammasomes and Pyroptosis of Liver Cells in Liver Fibrosis.

Authors:  Can Gan; Qiuyu Cai; Chengwei Tang; Jinhang Gao
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 4.  The Purinergic P2X7 Receptor-NLRP3 Inflammasome Pathway: A New Target in Alcoholic Liver Disease?

Authors:  Brendan Le Daré; Pierre-Jean Ferron; Thomas Gicquel
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

5.  Hemistepsin A inhibits T0901317-induced lipogenesis in the liver.

Authors:  Jae Kwang Kim; Il Je Cho; Eun Ok Kim; Dae Geon Lee; Dae Hwa Jung; Sung Hwan Ki; Sae Kwang Ku; Sang Chan Kim
Journal:  BMB Rep       Date:  2021-02       Impact factor: 4.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.